Article3 Biotech2025
Multi-targeted approach via apigenin-7-O-glucoside for therapeutic intervention of Tau phosphorylating kinases in Alzheimer's disease.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Irilone and Lupinisoflavone C as Potential Plant-Based Modulators of S1PR1 for Neuroimmune Modulation in Multiple Sclerosis: Insights from Molecular Docking and Dynamics.Journal of molecular neuroscience : MN · 2025Article
- Screening and experimental validation of modified Gandou Decoction-targeted inhibitors for alleviating AD components via network pharmacology, machine learning, and molecular dynamics simulation.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is one of the leading tauopathies in which several kinases phosphorylate Tau in response to Aβ oligomers, inflammation, calcium dysregulation, oxidative stress, mitochondrial dysfunction, or disruption of the key signaling pathways. Tau is phosphorylated by Ser/Thr kinases such as GSK3β, CDK5, MAPK14, and MARK2, as well as Tyr kinases like Fyn. Given the large crosstalk among these kinases, targeting one of these kinases is ineffective in treating tauopathies such as AD, highlighting the need for a multi-targeted approach. In this study, we targeted key kinases involved in Tau hyperphosphorylation using compounds derived from the medicinal plant Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-025-04413-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.